



**FOR IMMEDIATE RELEASE**

**MEDIA CONTACT:**

Theresa Hennessey Barcy  
[theresa@tmhpublicrelations.com](mailto:theresa@tmhpublicrelations.com)  
773-960-7276

**SYMETRIA HEALTH® PARTNERS WITH THE NATIONAL ASSOCIATION  
OF DRUG DIVERSION INVESTIGATORS (NADDI) AS A CORPORATE MEMBER**

*Symetria provides expertise and critical oversight to advance  
the fight against prescription and synthetic opioid diversion*

**CHICAGO, Wednesday, April 3, 2019** – **Symetria Health®** has partnered with the **National Association of Drug Diversion Investigators (NADDI)** as a new corporate member to advance its fight against pharmaceutical drug misuse and abuse.

**Bill Maloney, M.S., Director of Corporate Affairs at Symetria Health** and former Drug Enforcement Administration agent, was instrumental in developing the partnership with NADDI and will provide key insights and expertise on the protocols being implemented to prevent diversion and abuse of opioids at Symetria Recovery Centers across the country.

“Seventy percent of the people treated in Symetria Recovery Centers are victims of pharmaceutical opioids,” said **Maloney**. “We are looking forward to working closely with NADDI to share our expertise and evidence-based best practices to combat the diversion of suboxone and address the implications of the deadly emergence of synthetic opioids such as fentanyl in securing the long-term protection of patients.”

“We are honored to welcome Symetria Health as a new corporate member of NADDI,” said **Charlie Cichon, Executive Director of NADDI**. “Symetria will provide a critical perspective necessary to assist our members in investigating and preventing pharmaceutical drug diversion, specifically as it applies to the escalating public health crisis of opioid addiction.”

“The ‘fentanyl factor’ has created a need for treatment providers to respond to a new dynamic in diversion protocols. Symetria Health is now testing for fentanyl in its standard intake screening. Symetria has also achieved superior outcomes compared to national averages for most recovery markers, and has developed a specific and direct clinical response to the deadly emergence of fentanyl,” said **Maloney**.

To learn more about Symetria Health, visit [www.symetriahealth.com](http://www.symetriahealth.com) and follow [@SymetriaCenters](https://twitter.com/SymetriaCenters) on Twitter and [@SymetriaRecovery](https://www.facebook.com/SymetriaRecovery) on Facebook and Instagram.

###

**About Symetria Health**

Symetria Health® is an innovative behavioral health company focused on improving substance abuse treatment outcomes and strengthening communities by increasing awareness, advocacy and implementing best practices in the coordination of patient care.